Arcutis Biotherapeutics, Inc.’ roflumilast foam product has passed an advanced seborrheic dermatitis study prompting filing plans but experts are more invested in a potentially “transformational” psoriasis approval expected in July.
Arcutis Enjoys Seborrheic Dermatitis Win But Experts Itching For Psoriasis Approval
The firm is planning a US NDA filing after its roflumilast formulation succeeded in a pivotal seborrheic dermatitis study but analysts are keener on a ‘make or break’ approval in psoriasis.
